Navigation Links
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
Date:9/5/2012

LOS ANGELES and ROCKVILLE, Md., Sept. 5, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc. Under the terms of the agreement, ImaginAb will develop an anti-CD3 clinical imaging product, for which MacroGenics may receive future milestones and royalties.  In addition, ImaginAb will support the development of companion imaging agents for B7-H3, a novel immune regulator target for which MacroGenics is developing therapeutics.

"Collaborating with MacroGenics provides the opportunity to demonstrate the ways in which ImaginAb's antibody fragment-based imaging technology can be used at the clinical nexus between cancer and immunology," said Dr. Christian Behrenbruch, Chief Executive Officer of ImaginAb. "We are glad to partner on both the B7-H3 and CD3 imaging programs as they are high-potential targets for the treatment of cancer and autoimmune diseases. The  recent clinical successes around key immune-directed targets in cancer, including those involving members of the B7 family of proteins, make these areas of research especially exciting. Our collaboration will augment ImaginAb's existing CD8 development program with an anti-CD3 imaging program."

"Imaging immune function is the next frontier of diagnostic medicine and will have a major impact on how new therapeutics are developed for cancer and autoimmune diseases," commented Dr. Scott Koenig, CEO of MacroGenics. "Our collaboration with ImaginAb should benefit our internal development programs targeting CD3 and B7-H3."   

Under the terms of the agreement, ImaginAb will develop a clinical imaging strategy based on a MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing clinical programs, and will engineer a high-performance CD3 binding fragment for
'/>"/>

SOURCE ImaginAb, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
2. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
3. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
4. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
5. GNS Healthcare And CHDI Foundation Collaborate To Build Computer Model Of Huntingtons Disease
6. CeeTox and Cellular Dynamics Collaborate to Offer Predictive In Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells
7. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
8. Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa
9. Sanofi US Launches Collaborate Activate Innovation Challenge
10. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
11. AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015   Hospira, Inc. (NYSE: ... Drug Administration (FDA) on today,s FDA approval of the first ... is a watershed moment for improving patient access to safe, ... provider of biosimilars, Hospira has seen first-hand the positive impact ... participant in these early stages of the development of a ...
(Date:3/6/2015)... 2015  Unfors RaySafe, Marktführer für Lösungen ... European Congress of Radiology (ECR) in ... Installation seines Systems zur Strahlendosimetrie RaySafe i2. ... Das RaySafe i2 ist ... über die Dosis der Röntgenstreustrahlung gibt, der ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
... 31 AlphaVax, Inc.,announced today that it has concluded ... influenza vaccine based on its proprietary replicon vector,platform. This ... this,unique vector system as well as the feasibility of ... placebo-controlled, randomized, double-blind trial in,healthy adults, 18-40 years old, ...
... Oct. 31 Palatin Technologies,Inc. (AMEX: PTN ... a Phase 1,clinical trial of PL-3994, a long ... treatment of acute decompensated congestive,heart failure (CHF). The ... application Palatin submitted to the U.S. Food and ...
Cached Medicine Technology:AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial 2Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 3
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 Ticket Down ... at Levi's® Stadium in Santa Clara, California. This ... already hosted a plethora of exciting events. , The “Kick ... bring his popular summer tour to the west coast and ... art facility will take place on August 29 and fans ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... known as the pharmacokinetics of a drug refers to ... pharmaceutical compound inside an organism. When toxicity studies are ... or ADMET or ADME/Tox. Increasing focus on lowering costs ... of ADME-toxicology testing worldwide. The traditional drug development model ...
(Date:3/6/2015)... Parents need to start the discourse with their ... School programs like DARE, or Drug Abuse Resistance Education ... Overdose Prevention and Education has already impacted a collective ... on Feb. 27th. As teens continue to suffer fatal ... proponents are lobbying Florida to pass The Overdose Prevention ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
Breaking Medicine News(10 mins):Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... Khan Saturday underwent a successful prostate cancer operation at ... who led a team of doctors through the operation, ... ,The 66-year-old Khan, who pioneered Pakistan's nuclear programme, ... the first time he was moved out since his ...
... experts on the genetics of a potentially lethal heart ... athletes report they have greatly narrowed //the hunt for ... ,Their new findings, described in the July ... increase the accuracy of tests to identify those at ...
... Epilepsy is a condition that is caused by the disturbance ... cells to each other. People with epilepsy must be careful ... way. // ,The National Epilepsy Foundation says that ... such as stroke or a tumor, or the disease can ...
... University has provided an insight into how effective the lead ... otter species, examination of the otters killed by cars //since ... The research gives a valuable pointer for human health as ... the brain, as well as affect the kidney. ...
... annual meeting of the American society of plastic surgeons, 'Plastic ... surgery.// ,The convention that is to be held ... Francisco is to be attended by more than 6,000 doctors, ... ,It is expected that Plastic Surgery 2006 would ...
... University School of Medicine in St. Louis have requested authorities ... use of all-terrain vehicles (ATVs). This call was issued after ... no experience or training in driving motorized vehicles, and they're ... coming up ahead of them very well,' says T.S. Park, ...
Cached Medicine News:Health News:Closing in on Lethal Heart Rhythm in Young Athletes 2Health News:Closing in on Lethal Heart Rhythm in Young Athletes 3Health News:Annual Conference Of Plastic Surgeons In US To Focus On The Future Of Plastic Surgery 2Health News:Call To Ban Use Of ATVs By Children 2
... copolymer maintains almost all its mechanical strength ... loss in 915 months. Blunt thread design ... sizes to maximize surgeons options. Driver ... screw to help prevent the screw from ...
... positive attributes of the IMMULITE 2000, the ... of Logic Driven Incubation (LDI). Using a ... to be formatted for optimal performance with ... certain assays, such as Siemens Diagnostics' cardiac ...
... The Asnis III™ Cannulated Screw System ... 2 and TCS Systems and combined them ... cannulated screws in both titanium and stainless ... Screw System is designed to optimize surgical ...
... is part of a series of modular systems ... from 3.5 to 8.0 mm. Matching a combination ... provides convenience and flexibility for the orthopaedic surgeon ... may be customized using two of three screw ...
Medicine Products: